Clinical Trial Update: Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ [Phase 1]

View source ↗

Summary

Phase 1/1b trial of rilotumumab in Japanese patients with advanced solid tumors and advanced or metastatic gastric or GEJ cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Rilotumumab (AMG 102) (rilotumumab)

Snippet

Sponsor: Amgen | Conditions: Part 1- Advanced Solid Tumors, Part 2- Advanced or Metastatic Gastric Cancer | Phase 1 | Status: COMPLETED